Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drug
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
3don MSN
A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.
Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Jan 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the ...
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback